ARCT (Arcturus Therapeutics Holdings Inc.) Stock Financials & Earnings | Market Cap Arena

ARCT (Arcturus Therapeutics Holdings Inc.) Stock Financials & Earnings | Market Cap Arena

ARCTArcturus Therapeutics Holdings Inc.

Mkt Cap$217M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$78M

Net Income (TTM)$10M

EPS (TTM)-$2.40

Free Cash Flow (TTM)-$75M

Gross Margin124.1%

Op. Margin-97.5%

Net Margin12.9%

FCF Margin-95.5%

P/S Ratio (TTM)2.8x

P/E Ratio (TTM)21.4x

YoY Rev Growth-43.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$80M	$29M	$15M
Q2 23	$11M	$7M	-$55M
Q3 23	$43M	$43M	-$19M
Q4 23	$25M	$25M	-$18M
Q1 24	$33M	$33M	-$30M
Q2 24	$46M	$46M	-$21M
Q3 24	$39M	$39M	-$11M
Q4 24	$21M	$21M	-$33M
Q1 25	$29M	$29M	-$17M
Q2 25	$25M	$25M	-$12M
Q3 25	$17M	$14M	-$17M
Q4 25	$7M	$29M	-$31M

Valuation

Quarter	P/S	P/E
Q1 23	0.8x	1.9x
Q2 23	0.8x	2.7x
Q3 23	0.7x	2.2x
Q4 23	1.4x	—
Q1 24	1.9x	—
Q2 24	1.5x	—
Q3 24	1.5x	—
Q4 24	1.6x	—
Q1 25	1.6x	—
Q2 25	1.9x	—
Q3 25	2.4x	—
Q4 25	2.8x	21.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$36M	-$37M
Q2 23	$51M	$50M
Q3 23	-$32M	-$33M
Q4 23	-$629K	-$2M
Q1 24	-$6M	-$6M
Q2 24	-$30M	-$30M
Q3 24	-$24M	-$24M
Q4 24	-$284K	-$284K
Q1 25	-$35M	-$35M
Q2 25	-$6M	-$6M
Q3 25	-$17M	-$17M
Q4 25	-$16M	-$16M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$691K
Q2 23	$354K
Q3 23	$981K
Q4 23	$875K
Q1 24	$240K
Q2 24	$328K
Q3 24	$80K
Q4 24	$0
Q1 25	$137K
Q2 25	$0
Q3 25	$181K
Q4 25	$138K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+1431.0%	+17.8%
Q2 23	-61.2%	+34.0%
Q3 23	+224.5%	+24.9%
Q4 23	-84.4%	+11.6%
Q1 24	-59.4%	-3.8%
Q2 24	+337.1%	+1.8%
Q3 24	-10.5%	-21.0%
Q4 24	-16.3%	+25.5%
Q1 25	-9.9%	-26.7%
Q2 25	-46.7%	-46.2%
Q3 25	-55.8%	-32.1%
Q4 25	-65.7%	-29.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$8M	10.2%
Q2 23	$8M	79.7%
Q3 23	$9M	21.4%
Q4 23	$9M	35.2%
Q1 24	$10M	30.9%
Q2 24	$9M	20.5%
Q3 24	$9M	24.5%
Q4 24	$9M	42.8%
Q1 25	$7M	22.7%
Q2 25	$6M	25.3%
Q3 25	$6M	33.4%
Q4 25	$7M	94.7%

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$52M	$14M
Q2 23	$53M	$13M
Q3 23	$51M	$13M
Q4 23	$37M	$13M
Q1 24	$54M	$15M
Q2 24	$59M	$12M
Q3 24	$39M	$13M
Q4 24	$44M	$12M
Q1 25	$35M	$11M
Q2 25	$30M	$10M
Q3 25	$23M	$10M
Q4 25	$24M	$14M

Revenue Segments

Quarter	Collaboration Revenue	Grant
Q1 23	$80M	$556K
Q1 25	$25M	$4M
Q3 25	$14M	$3M
Q4 25	$3M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$328M	$0	$328M
Q2 23	$323M	$0	$323M
Q3 23	$312M	$0	$312M
Q4 23	$292M	$0	$292M
Q1 24	$288M	$0	$288M
Q2 24	$315M	$0	$315M
Q3 24	$237M	$0	$237M
Q4 24	$237M	$0	$237M
Q1 25	$217M	$0	$217M
Q2 25	$196M	$0	$196M
Q3 25	$180M	$0	$180M
Q4 25	$231M	$0	$231M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	27M	+0.3%
Q2 23	27M	-2.2%
Q3 23	27M	+0.0%
Q4 23	27M	+0.2%
Q1 24	27M	+0.9%
Q2 24	27M	+0.3%
Q3 24	27M	+0.4%
Q4 24	27M	-0.2%
Q1 25	27M	+0.4%
Q2 25	27M	+0.1%
Q3 25	27M	+0.2%
Q4 25	27M	+0.7%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	$236K	88
FY 20	$81K	118
FY 21	$70K	177
FY 22	$1M	170
FY 23	$876K	180
FY 24	$786K	176
FY 25	$410	200K